Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases
November 21, 2024 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases
KFSHRC Madinah’s Virtual Clinics Wins Award at PX Congress
November 21, 2024 01:08 ET
|
King Faisal Specialist Hospital & Research Centre
KFSHRC Madinah’s Virtual Clinics Wins Award at PX Congress
Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference
November 20, 2024 08:30 ET
|
Silexion Therapeutics Corp
GRAND CAYMAN, CAYMAN ISLANDS, Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers,...
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting
November 20, 2024 08:00 ET
|
CG Oncology Inc.
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting
Rita and Alex Hillman Foundation Awards $250,000 to Expand Home-Based Rural Cancer Care
November 19, 2024 11:00 ET
|
Rita & Alex Hillman Foundation
The Rita and Alex Hillman Foundation awards grant to Rural Huntsman at Home to expand home-based cancer care for rural populations in the Western U.S.
Biolojic Design Joins Johnson & Johnson Innovation - JLABS
November 19, 2024 08:00 ET
|
Biolojic Design
Biolojic Design expands U.S. presences by becoming a resident company at Johnson & Johnson JLABS DC
AIM ImmunoTech Announces Publication of Breast Cancer Data from Roswell Park Comprehensive Cancer Center in The Journal for ImmunoTherapy of Cancer
November 19, 2024 08:00 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., Nov. 19, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that data were published on Roswell Park Comprehensive Cancer...
ICPO Foundation kooperiert mit Munich Precision Oncology (MPO), um weltweit spezialisierte Theranostik-Zentren zu etablieren
November 19, 2024 01:30 ET
|
ICPO Foundation
Das Münchener Pilotzentrum wird als funktionaler Demonstrator für die ICPO dienen. Die Foundation stellt Akkreditierungsrichtlinien und zertifizierte Schulungen bereit, um die Behandlungserfolge der...
ICPO Foundation partners with Munich Precision Oncology (MPO) to establish dedicated theranostics centers globally
November 19, 2024 01:30 ET
|
ICPO Foundation
The Munich pilot center will serve as a functional demonstrator for ICPO. The Foundation will provide accreditation guidelines and certified training for improved patient outcomes. November 19, 2024...
Siren Biotechnology Reveals SRN-101 as Lead Asset for High-Grade Gliomas with Both Orphan Drug and Rare Pediatric Disease Designations from the FDA
November 18, 2024 11:00 ET
|
Siren Biotechnology, Inc.
Siren Biotechnology reveals SRN-101 as lead asset for high-grade gliomas with both Orphan Drug and Rare Pediatric Disease Designations from the FDA